Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.
Thank you. Please check your inbox to confirm.
A federal biosafety and ethics panel on Tuesday unanimously approved the first study in cancer patients of the genome-editing technology CRISPR/Cas9.
Support Provided By: